Target & Activity
| Target | Activity | Value |
|---|---|---|
| HIV integrase (Cell-free assay) | 2.7 nM |
Cellular Effect
| Cell Line | Activity | Value | Description | Reference |
|---|---|---|---|---|
| CHO | IC50 | > 100 μM | Inhibition of human OATP1B1 expressed in CHO cells using [3H]estradiol 17beta-D-glucuronide as substrate by liquid scintillation counting analysis | [PMID: 23132334] |
| HEK293 | IC50 | > 100 μM | Inhibition of human OATP1B3 expressed in BacMam baculovirus virus infected HEK MSR2 cells using [3H]estradiol 17beta-D-glucuronide as substrate by liquid scintillation counting analysis | [PMID: 23132334] |
| HEK-293T | IC50 | 1.7 nM | Antiviral activity against pseudo Human immunodeficiency virus infected in HEK293T cells after 2 days | [PMID: 23845180] |
| HEK-293T | IC50 | 22 nM | Antiviral activity against pseudo Human immunodeficiency virus infected in HEK293T cells after 2 days in presence of human serum albumin | [PMID: 23845180] |
| HOS | EC50 | 1.6 nM | Antiviral activity against HIV-1 harboring wild type integrase infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay | [PMID: 24901667] |
| HOS | EC50 | 11 nM | Antiviral activity against INSTI-resistant HIV-1 harboring integrase R263K mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay | [PMID: 24901667] |
| HOS | EC50 | 13 nM | Antiviral activity against INSTI-resistant HIV-1 harboring integrase G118R mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay | [PMID: 24901667] |
| HOS | EC50 | 3.6 nM | Antiviral activity against raltegravir-resistant HIV-1 harboring integrase N155H mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay | [PMID: 24901667] |
| HOS | EC50 | 4.3 nM | Antiviral activity against raltegravir-resistant HIV-1 harboring integrase Y143R mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay | [PMID: 24901667] |
| HOS | EC50 | 5.8 nM | Antiviral activity against raltegravir-resistant HIV-1 harboring integrase G140S/Q148H double mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay | [PMID: 24901667] |
| MDCK-II | IC50 | > 100 μM | Inhibition of MDR1 (unknown origin) expressed in MDCK2 cells assessed as basolateral to apical transport of [3H]digoxin after 90 mins by liquid scintillation counting analysis | [PMID: 23132334] |
| MDCK-II | IC50 | > 30 μM | Inhibition of BCRP (unknown origin) expressed in MDCK2 cells assessed as basolateral to apical transport of [14C]cimetidine after 90 mins by liquid scintillation counting analysis | [PMID: 23132334] |
| MDCK-II | IC50 | 1.9 μM | Inhibition of human OCT2 expressed in MDCK2 cells using [14C]metformin as substrate by liquid scintillation counting analysis | [PMID: 23132334] |
| MT4 | IC50 | 2 nM | Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells after 4 to 5 days by bioluminescence assay | [PMID: 23845180] |
| Sf9 | IC50 | > 100 μM | Inhibition of human MRP2 expressed in baculovirus-infected Sf9 cell membrane vesicle using [3H]estradiol 17beta-D-glucuronide as substrate preincubated with vesicles for 5 mins prior to substrate addition by liquid scintillation counting analysis | [PMID: 23132334] |
| Vero C1008 | CC50 | > 40 μM | Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm) | 10.1101/2020.04.03.023846 |
| Vero C1008 | EC50 | 22.04 μM | Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days | 10.1101/2020.04.03.023846 |
17 records · Scroll to view more